Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare kidney disease? first human trial of CPV-104 begins

NCT ID NCT07483827

Recruiting now Disease control Sponsor: eleva GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receiving a single dose, and C3G patients receiving four weekly doses. The main goal is to check safety and how the body handles the drug, not yet whether it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CPV-104
What this could lead to
If safe, this could pave the way for a treatment that controls C3 glomerulopathy, a rare kidney disease with few options.
What could go wrong
This is a very early Phase 1 trial focused only on safety, not effectiveness. It is small (39 people) and may not lead to a working treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY (C3G) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3 GLOMERULOPATHY (C3G) HEALTHY ADULT PARTICIPANTS

Contacts and locations

Locations

  • Amsterdam UMC Stichting

    RECRUITING

    Amsterdam, Netherlands

  • Centre Hospitalier Universitaire De Toulouse

    RECRUITING

    Toulouse, France

  • Clinica Universidad De Navarra

    RECRUITING

    Pamplona, Spain

  • Cliniques universitaires Saint-Luc

    RECRUITING

    Brussels, Belgium

  • Fakultni Thomayerova nemocnice

    RECRUITING

    Prague, Czechia

  • Fundacio Puigvert

    NOT_YET_RECRUITING

    Barcelona, Spain

  • Hospital Curry Cabral - Centro Hospitalar de Lisboa Central - ULS Sao José

    RECRUITING

    Lisbon, Portugal

  • Hospital Universitario 12 De Octubre

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Virgen De La Macarena

    RECRUITING

    Seville, Spain

  • Hôpital Européen Georges-Pompidou HEGP

    RECRUITING

    Paris, France

  • Karolinska University Hospital

    RECRUITING

    Huddinge, Sweden

  • Laiko General Hospital Of Athens

    RECRUITING

    Athens, Greece

  • Medizinische Universität Wien

    RECRUITING

    Vienna, Austria

  • Pauls Stradins Clinical University Hospital

    RECRUITING

    Riga, Latvia

  • University Clinical Center of Serbia

    NOT_YET_RECRUITING

    Belgrade, Serbia

  • University Hospital Virgen Del Rocio S.L.

    RECRUITING

    Seville, Spain

  • Vilnius University Hospital Santaros Klinikos

    RECRUITING

    Vilnius, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.